Ottmann, Oliver - Cardiff University

个人简介

Prof. Ottmann has led the development of novel drugs and highly targeted approaches, including immunotherapies and molecularly directed agents. He has served as principal investigator on numerous national and international First in Human, Phase I, II, and III clinical studies of many novel agents. His clinical and research efforts have been focused on providing therapy for patients suffering from treatment-resistant or refractory leukemia, with a special emphasis on acute lymphoblastic leukaemia and on interrogating the mechanisms of resistance to targeted therapy. He has over 250 peer-reviewed publications focused on haematology developmental therapeutics, and has particular interests in the mentoring of physician-scientists working on developmental therapeutics, as well as in developing national and international collaborations across the bioscience spectrum.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Oelsner, S.et al. 2016. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma. Cytotherapy (10.1016/j.jcyt.2016.10.009) Oelsner, S.et al. 2016. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival. International Journal of Cancer 139(8), pp. 1799-1809. (10.1002/ijc.30217) Giebel, S.et al. 2016. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the. Cancer 122(19), pp. 2941-2951. (10.1002/cncr.30130) Wojcik, B.et al. 2016. Plastic surface marker expression in adult acute lymphoblastic leukemia explains ambiguity of leukemia-initiating stem cell populations. Experimental Hematology 44(9), pp. S108-S108. (10.1016/j.exphem.2016.06.240) Rousselot, P.et al. 2016. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood 128(6), pp. 774-782. (10.1182/blood-2016-02-700153) Rousselot, P.et al. 2016. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood 128(6), pp. 774-782. (10.1182/blood-2016-02-700153) Haense, N.et al. 2016. A phase I trial of the trifunctional anti Her2 x anti CD3 antibody ertumaxomab in patients with advanced solid tumors. BMC Cancer 16, pp. 420. (10.1186/s12885-016-2449-0) Romanski, A.et al. 2016. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. Journal of Cellular and Molecular Medicine 20(7), pp. 1287-1294. (10.1111/jcmm.12810)